Kenjiro Kimura, Tatsuo Hosoya, Shunya Uchida, Masaaki Inaba, Hirofumi Makino, Shoichi Maruyama, Sadayoshi Ito, Tetsuya Yamamoto, Yasuhiko Tomino, Iwao Ohno, Yugo Shibagaki, Satoshi Iimuro, Naohiko Imai, Masanari Kuwabara, Hiroshi Hayakawa, Hiroshi Ohtsu, Yasuo Ohashi, Seiichi Matsuo, Hisashi Yamanaka, Tadao Akizawa, Tamio Teramoto, Hiroshi Kasanuki, Kenichi Yoshimura, Hiroshi Sato, Satoshi Horikoshi, Syoichi Maruyama, Masahiko Inaba, Yuji Moriwaki, Haruhito Uchida, Nagayuki Kaneshiro, Hidekazu Moriya, Yasuhiro Komatsu, Shinya Kaname, Kazunari Hanaoka, Makoto Ogura, Masato Ikeda, Kenji Kasai, Akira Sugiura, Kazushi Takahashi, Kenichiro Kojima, Kosaku Nitta, Hirofumi Tamai, Hiroshi Nagaya, Senji Okuno, Ryusuke Kakiya, Hiroya Takeoka, Kyouji Hirata, Kenichiro Asano, Yasuo Fukaya, Yasushi Iwaida, Yasuo Tsuneda, Shigeaki Nishimura, Takeyuki Hiramatsu, Yoshitaka Isaka, Takafumi Ito, Yukio Yuzawa, Kunihiro Yamagata, Tadashi Sofue, Yoshimi Jinguji, Keita Hirano, Kazuhiro Matsuyama, Teruhiko Mizumoto, Yuko Shibuya, Masahiro Sugawara, Moritoshi Kadomura, Yasuaki Teshima, Hiroshi Ohtani, Hiroki Kamata, Susumu Okawara, Masaki Fukushima, Katsumi Takemura, Eriko Kinugasa, Masami Kogure, and Yoichi Ehara
Rationale & Objective Epidemiologic and clinical studies have suggested that urate-lowering therapy may slow the progression of chronic kidney disease (CKD). However, definitive evidence is lacking. Study Design Randomized, double-blind, placebo-controlled trial. Setting & Participants 467 patients with stage 3 CKD and asymptomatic hyperuricemia at 55 medical institutions in Japan. Intervention Participants were randomly assigned in a 1:1 ratio to receive febuxostat or placebo for 108 weeks. Outcomes The primary end point was the slope (in mL/min/1.73 m2 per year) of estimated glomerular filtration rate (eGFR). Secondary end points included changes in eGFRs and serum uric acid levels at 24, 48, 72, and 108 weeks of follow-up and the event of doubling of serum creatinine level or initiation of dialysis therapy. Results Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. There was no significant difference in mean eGFR slope between the febuxostat (0.23 ± 5.26 mL/min/1.73 m2 per year) and placebo (−0.47 ± 4.48 mL/min/1.73 m2 per year) groups (difference, 0.70; 95% CI, −0.21 to 1.62; P = 0.1). Subgroup analysis demonstrated a significant benefit from febuxostat in patients without proteinuria (P = 0.005) and for whom serum creatinine concentration was lower than the median (P = 0.009). The incidence of gouty arthritis was significantly lower (P = 0.007) in the febuxostat group (0.91%) than in the placebo group (5.86%). Adverse events specific to febuxostat were not observed. Limitations GFR was estimated rather than measured, and patients with stages 4 and 5 CKD were excluded. Conclusions Compared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia. Funding Funded by Teijin Pharma Limited. Trial Registration Registered at the UMIN (University Hospital Medical Information Network) Clinical Trials Registry with study number UMIN000008343.